Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication
Ciclesonide (Cic) is approved as an inhalant for asthma and was clinically tested as a candidate therapy for coronavirus disease 2019 (COVID-19). Its active metabolite Cic2 was recently reported to suppress genomic RNA replication of severe acute respiratory syndrome coronavirus 2. In this study, we...
I tiakina i:
Ngā kaituhi matua: | , , , , , , , , |
---|---|
Hōputu: | Pukapuka |
I whakaputaina: |
Elsevier,
2022-07-01T00:00:00Z.
|
Ngā marau: | |
Urunga tuihono: | Connect to this object online. |
Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ipurangi
Connect to this object online.3rd Floor Main Library
Tau karanga: |
A1234.567 |
---|---|
Tārua 1 | Wātea |